Suppr超能文献

趋化因子受体小分子拮抗剂——杂乱无章是美德吗?

Small molecule antagonists of chemokine receptors--is promiscuity a virtue?

机构信息

Leukocyte Biology Section, National Heart and Lung Institute, Faculty of Medicine, Imperial College of Science, Technology & Medicine, South Kensington Campus, London SW7 2AZ, UK.

出版信息

Curr Top Med Chem. 2010;10(13):1351-8. doi: 10.2174/156802610791561228.

Abstract

A major function of the chemokine system is to coordinate the recruitment of leukocytes to specific locations within the tissues. The involvement of chemokine receptors in a multitude of inflammatory diseases, coupled with their belonging to the highly "druggable" GPCR superfamily, makes them excellent candidates for the development of novel drugs by the pharmaceutical industry. Despite descriptions in the literature of many specific small molecule chemokine receptor antagonists, none have yet shown efficacy in the clinical inflammatory setting. In this article, we discuss the successes and failures of chemokine receptor antagonists in the clinic and review a subset of molecules that are documented as having activity at two or more chemokine receptors. It may be that a more permissive approach, targeting several chemokine receptors with a single molecule will provide the next generation of anti-inflammatory drugs.

摘要

趋化因子系统的一个主要功能是将白细胞募集到组织内的特定位置。趋化因子受体在多种炎症性疾病中的参与,加上它们属于高度“可成药”的 G 蛋白偶联受体超家族,使它们成为制药行业开发新型药物的理想候选者。尽管文献中描述了许多特定的小分子趋化因子受体拮抗剂,但没有一种在临床炎症环境中显示出疗效。在本文中,我们讨论了趋化因子受体拮抗剂在临床中的成功和失败,并回顾了一组被证明对两种或多种趋化因子受体具有活性的分子。可能需要一种更宽松的方法,用单个分子靶向几种趋化因子受体,才能提供下一代抗炎药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验